Connect with us

Press Releases

Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors

Dr. Donnenfeld brings significant clinical leadership and innovation experience to expand company’s board of directors.




(PRESS RELEASE) SEATTLE, WA — Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery and is one of the leading refractive and cataract surgeons in the United States.

“I am thrilled to welcome Eric to the Visus Board,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Eric brings tremendous leadership experience, not only as a world-renowned anterior segment specialist, but also in business management and innovation. He is the founding partner in OCLI Vision, one of the leading ophthalmology and optometry practices in the United States, and he has been involved in numerous clinical stage companies. We look forward to Eric’s many contributions as Visus advances and expands on its pipeline of innovative ophthalmic products.”

“Over the last two decades, I have had the honor of working closely with Eric on some of the most successful and challenging development programs in eyecare,” said Rhett Schiffman, M.D., M.S., M.H.S.A., co-founder, chief medical officer and head of research and development at Visus Therapeutics. “He is the premier clinician scientist and has played a key role in the clinical development of many of the most important therapies for the front of the eye. As Visus looks to change the way the leading causes of visual disability are treated, we look forward to Eric’s guidance.”

“I am very much looking forward to working closely with Ben and Rhett, the Board and leadership team, as Visus pioneers many exciting new investigational drug candidates, including what may be a best-in-class topical treatment of presbyopia—BRIMOCHOL PF,” said Dr. Donnenfeld. “Beyond that, Visus’ recently announced lens modulation program offers the real possibility of a non-surgical therapy that has the potential to treat cataracts and presbyopia, improving the quality of life of millions of people around the world. I am really excited to help Visus bring these and other potentially transformative treatments to our patients.”



The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular